Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

An experimental therapy for Parkinson's disease being developed by ... significant extension in the time to motor progression in patients with early-stage Parkinson's compared to placebo, missing ...

investigated prasinezumab in almost 600 people with early-stage Parkinson's disease. The treatment showed potential clinical effect, including a delay in motor progression, as well as consistent ...

Background Progressive supranuclear palsy and Parkinson's disease have characteristic clinical and neuropathologic profiles, but also share overlapping clinical features. This study aimed to ...

Although the PADOVA study missed the primary endpoint, treatment with prasinezumab indicated possible benefits in early-stage Parkinson’s disease, a progressive degenerative disorder of the ...

announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson's disease, treated for a minimum of 18 months while on stable symptomatic ...